The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy

Abstract

Background:

The Khorana score is a predictive risk model for venous thromboembolism (VTE) in patients with cancer planning to receive chemotherapy. Urothelial carcinoma and variant histologies (UC/VH) were underrepresented in the model. We sought to evaluate whether the Khorana score predicts for VTE in a retrospective multinational data set of patients with metastatic UC/VH.

Methods:

Patients diagnosed with metastatic UC/VH who received chemotherapy were eligible. Those with incomplete or miscoded data were excluded. Khorana scores were calculated based on the pretreatment data and categorized into high (≥3) or intermediate (1-2) VTE risk. Other patient-, tumor-, and therapy-related factors were also analyzed. The χ² and logistic regression analyses were used to assess differences in VTE rates based on the clinical characteristics. Subgroup analyses were performed to evaluate the Khorana score and associated variables for early (<3 months) and late (>3 months) VTE.

Results:

A total of 943 patients were eligible for analysis. The cumulative VTE rate was 9.9%. There was no statistical difference in overall VTE rate between Khorana high- and intermediate-risk groups (P = .16). In the multivariate analysis, nonurothelial histology (odds ratio [OR] = 2.56; P = .002) and the presence of cardiovascular disease (CVD) or CVD risk factors (OR = 2.14; P = .002) were associated with increased VTE risk. In the first 3 months from initiation of chemotherapy, Khorana high risk (OR = 2.08; P = .04) was associated with higher VTE rates. White blood cell (WBC) count (OR = 1.05; P = .04) was the only significant Khorana variable for early VTE.

Conclusions:

The Khorana score stratifies early but not overall VTE risk in patients with metastatic UC/VH. The WBC count drives the increased early VTE risk seen with the Khorana score.

Keywords

Khorana score leukocytosis bladder cancer venous thromboembolism chemotherapy

Introduction

Venous thromboembolism (VTE) is a common complication in the management of patients with cancer and is associated with increased morbidity and mortality.^1
–3 Compared to the general population, patients with cancer are at a 4- to 7-fold increased risk of developing a VTE.³ However, the risk of developing a VTE is not uniform across all patients and is dependent on various patient-, tumor-, and treatment-related factors. Nonetheless, individual risk factors alone are insufficient to identify a high-risk population who may benefit from primary thromboprophylaxis.

The Khorana score is a predictive risk assessment model for VTE in patients with cancer.⁴ Khorana et al identified 5 variables predictive for VTE: primary tumor site, body mass index, white blood cell (WBC) count, platelet count, and hemoglobin level or use of erythropoiesis-stimulating agents.⁴ The risk model then categorized patients into low (0), intermediate (1-2), or high risk (≥3), based on these variables. Subsequently, the Khorana score was validated in the Vienna Cancer and Thrombosis Study (CATS), a prospective, observational cohort study of 819 patients representing 10 different malignancies.⁵

Although the Khorana score is now a validated tool to stratify VTE risk in patients with cancer, urothelial carcinoma and variant histologies (UC/VH) were not well represented in these studies. In the original analysis, patients with bladder cancer were grouped into the “other” category, which only represented 10% of the study population.⁴ Moreover, in the CATS study, patients with UC/VH were not included in the analysis altogether.⁵ Yet, patients with genitourinary malignancies (excluding prostate cancer) are considered at “higher risk” and receive 1 point in the risk model. In this study, we sought to evaluate whether the Khorana score predicted for VTE in patients with metastatic UC/VH treated with systemic chemotherapy.

Methods

Study Design and Patient Population

The Retrospective International Study of Cancers of the Urothelium (RISC) is a multicenter, international retrospective study of the management and outcomes of patients who develop at least muscle-invasive UC/VH. Clinical data were extracted from patient charts and compiled via a password-protected data capture platform from 29 international academic centers with previously described methods.⁶ All participating institutions were granted approval by their respective institutional review boards.

Patients diagnosed with metastatic disease of the bladder, urethra, or upper urinary tract (renal pelvis or ureter) who were subsequently treated with systemic chemotherapy were eligible for analysis. All patients were required to have complete information on all the Khorana score variables for inclusion in the analysis. Patients with miscoded data were excluded. Any patient without a date of diagnosis of metastatic disease or VTE data was also excluded. The VTE incidence stratified by Khorana risk group was the primary end point of this analysis. A VTE was defined as a deep vein thrombosis, pulmonary embolism, catheter-associated thrombosis, or other venous thrombosis (eg, splanchnic vein thrombosis); all diagnoses were assigned by local investigators without central radiographic adjudication. Khorana scores were calculated based on pretreatment data and categorized into high (≥3) or intermediate (1-2) VTE risk. Low VTE risk score was not possible given the 1 point mandatory assignment for all patients in this analysis for their primary tumor site. Additionally, each individual Khorana score variable was independently assessed.

Other patient-, tumor-, and treatment-related factors were evaluated for their association with VTE risk. We have previously reported from the RISC database that nonurothelial histology, the presence of cardiovascular disease (CVD; coronary artery disease, peripheral vascular disease, or a cerebrovascular accident) or CVD risk factors (hypertension, diabetes mellitus, or hyperlipidemia), and renal dysfunction are associated with development of a VTE in the metastatic setting.⁷ Given that the patient cohort for this analysis is a subset of the prior study, these clinical characteristics were chosen a priori to be included in the multivariate analysis. Comorbidities captured in the database were derived from the Charlson comorbidity index.⁸ Those with at least 2% prevalence were further assessed for their association with VTE. Age, gender, race, primary tumor location, and primary tumor treatment with either surgery or radiotherapy were also evaluated.

Lastly, since the median follow-up in the development and validation cohorts of the Khorana score was 73 days, we hypothesized that the Khorana score may be more effective in predicting early VTE risk.⁴ Therefore, we performed a subgroup analysis of Khorana high or intermediate risk stratified by early (within the first 3 months) and late (after 3 months) VTE development following initiation of systemic chemotherapy.

Statistical Analysis

Cumulative VTE incidence was calculated from the time of initiation of first-line chemotherapy. For the univariate analysis, χ² and Fisher exact tests were used to evaluate differences in VTE rates when assessing categorical independent variables. When evaluating VTE rates based on continuous independent variables in the univariate analysis, simple logistic regression was applied. Khorana risk groups, a priori identified clinical characteristics, demographic variables (ie, age, gender, and race), and any statistically significant independent covariates in the univariate analysis (P ≤ .05) were planned to be included in the multivariate logistic regression model. The subgroup analyses were carried out using the same multivariate logistic regression model.

Results

Study Population and Patient Characteristics

Of the 3025 patients who comprise the RISC database, 1912 developed metastatic disease (Figure 1). Of these, 484 did not receive chemotherapy in the metastatic setting, and 485 had incomplete or miscoded data. Therefore, 943 patients were eligible for analysis. The baseline patient characteristics of the study cohort are shown in Table 1. The mean age was 66.0 years. Most patients’ primary tumor was located in the bladder (82.4%), and the most common histologic subtype was urothelial (91.5%).

Figure 1.

Flowchart of patient inclusion and exclusion for analysis.

Table 1.

Baseline Characteristics of Study Cohort.

Characteristics	N (%)
Age: mean ± SD	66.0 ± 10.0
Gender
Male	731 (77.5)
Female	207 (22.0)
Unknown	5 (0.5)
Race
Caucasian	863 (91.5)
Black	36 (3.8)
Asian	15 (1.6)
Hispanic	19 (2.0)
Unknown	10 (1.1)
Tumor location
Bladder	777 (82.4)
Other	149 (15.8)
Unknown	17 (1.8)
Histology
Urothelial	863 (91.5)
Nonurothelial	80 (8.5)
Primary treatment^a
Surgery	539 (57.2)
Radiotherapy	48 (5.1)
None/unknown	375 (39.8)

Abbreviation: SD, standard deviation.

^a19 patients treated with both surgery and radiotherapy.

Cumulative Incidence of VTE and Association With Clinical Characteristics

Unadjusted VTE incidence rates based on patient demographics and clinical characteristics are shown in Table 2. In all, there were 93 VTEs for a cumulative incidence of 9.9%. The VTE incidence rates for the high- and intermediate-risk groups were 13.0% (95% confidence interval [CI]: 8.2%-19.1%) and 9.2% (95% CI: 7.3%-11.5%), respectively. However, there was no statistically significant difference in cumulative VTE incidence between the 2 groups (P = .15). Additionally, none of the independent Khorana score variables were associated with increased VTE risk. Nonurothelial histology (P < .001), the presence of CVD or CVD risk factors (P = .001), and renal dysfunction (P = .03) were associated with the development of a VTE, as previously reported.⁷ No other clinical characteristics assessed achieved statistical significance in the univariate analysis.

Table 2.

Unadjusted Venous Thromboembolism Incidence Rates by Clinical Characteristics.

	VTE/N	VTE Rate (%)	95% CI	P Value
Total	93/943	9.9	8.0-12.0	–
Age^a	0.99^b		0.97-1.01	.41
Gender
Male	66/731	9.0	7.0-11.3	.09
Female	27/207	13.0	8.8-18.4
Race
Caucasian	83/863	9.6	7.7-11.8	.38
Other	9/70	12.9	6.1-23.0
Primary tumor location
Bladder	81/777	10.4	8.4-12.8	.26
Other	11/149	7.4	3.7-12.8
Histology
Urothelial	76/863	8.8	7.0-10.9	<.001
Nonurothelial	17/80	21.3	12.9-31.8
Primary treated with surgery
Surgery	48/539	8.9	6.6-11.6	.26
No surgery	45/404	11.1	8.2-14.6
Primary treated with radiation
Radiation	5/48	10.4	3.5-22.7	.81
No radiation	88/895	9.8	8.0-12.0
CVD or CVD risk factors
Yes	64/496	12.9	10.1-16.2	.001
No	29/447	6.5	4.4-9.2
Renal dysfunction
Yes	13/77	16.9	9.3-27.1	.03
No	80/866	9.2	7.4-11.4
COPD
Yes	6/82	7.3	2.7-15.3	.42
No	87/861	10.1	8.2-12.3
Congestive heart failure
Yes	2/26	7.7	1.0-25.1	1.00
No	91/917	9.9	8.1-12.0
Khorana risk group
High risk (≥3)	21/162	13.0	8.2-19.1	.15
Intermediate risk (1-2)	72/781	9.2	7.3-11.5
WBC count (WBC/uL)^a	1.00^b		0.96-1.05	.92
Hemoglobin (g/dL)^a	1.01^b		0.91-1.13	.82
Platelet count (plt/uL)^a	1.00^b		0.998-1.001	.67
Body mass index (kg/m²)^a	1.04^b		1.00-1.08	.08

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; VTE, venous thromboembolism; WBC, white blood cell.

^aCalculated as continuous variables.

^bResults indicate odds ratios for the given variables.

Multivariate Analysis of Clinical Characteristics and VTE

As previously reported,⁷ on multivariate analysis, nonurothelial histology (odds ratio [OR] = 2.56; 95% CI: 1.40-4.70; P = .002) and CVD or CVD risk factors (OR = 2.14; 95% CI: 1.31-3.48; P = .002) were associated with an increased incidence of VTE (Table 3). Patients stratified into the Khorana high-risk group did not have a statistically significant increase in VTE compared to patients with an intermediate-risk Khorana score (OR = 1.48; 95% CI: 0.86-2.53; P = .16). Renal dysfunction (OR = 1.69; 95% CI: 0.86-3.29; P = .13) also did not reach statistical significance. This may have been a result of a low absolute event rate and low prevalence of renal dysfunction in this study cohort, resulting in insufficient power to demonstrate a difference.

Table 3.

Multivariate Logistic Regression of Venous Thromboembolic Risk Based on Clinical Characteristics.

Clinical Characteristic	OR	95% CI	P Value
Khorana high risk	1.48	0.86-2.53	.16
Nonurothelial histology	2.56	1.40-4.70	.002
CVD or CVD risk factors	2.14	1.31-3.48	.002
Renal dysfunction	1.69	0.86-3.29	.13

Abbreviations: CI, confidence interval; CVD, cardiovascular disease; OR, odds ratio.

Multivariate Analysis of Association of Khorana Score With Early (<3 Months) and Late (>3 Months) VTE

On subgroup analysis, a high-risk Khorana score was associated with a statistically significant increase in early VTE (OR = 2.08; 95% CI: 1.04-4.15; P = .04) but not late VTE (OR = 0.94; 95% CI: 0.42-2.10; P = .89; Table 4). When assessing each variable comprising the Khorana score independently, only WBC count (OR = 1.05; 95% CI: 1.00-1.10; P = .04) was associated with a higher frequency of early VTE.

Table 4.

Multivariate Logistic Regression of Early (<3 Months) and Late (>3 Months) Venous Thromboembolism From Initiation of Systemic Therapy Based on Clinical Characteristics.

Clinical Characteristics	VTE/N (%)	OR	95% CI	P Value
Early VTE (<3 months)
Khorana risk group
High risk	13/162 (8.0)	2.08	1.04-4.15	.04
Intermediate risk	31/781 (4.0)	1.0	ref	ref
Khorana risk score variable
WBC count (WBC/uL)^a	N/A	1.05	1.00-1.10	.04
Hemoglobin (g/dL)^a	N/A	0.97	0.82-1.15	.73
Platelet count (plt/uL)^a	N/A	1.00	0.999-1.003	.38
Body mass index (kg/m²)^a	N/A	1.04	0.99-1.09	.17
Histology
Nonurothelial	6/80 (7.5)	1.60	0.64-4.01	.32
Urothelial	38/863 (4.4)	1.0	ref	ref
CVD or CVD risk factors
Yes	30/496 (6.1)	2.03	1.03-4.03	.04
No	14/447 (3.1)	1.0	ref	ref
Renal dysfunction
Yes	5/77 (6.5)	1.26	0.46-3.41	.65
No	39/866 (4.5)	1.0	ref	ref
Late VTE (>3 months)
Khorana risk group
High risk	8/162 (4.9)	0.94	0.42-2.10	.89
Intermediate risk	41/781 (5.3)	1.0	ref	ref
Khorana risk score variable
WBC count (WBC/uL)^a	N/A	0.93	0.84-1.02	.12
Hemoglobin (g/dL)^a	N/A	1.12	0.97-1.31	.13
Platelet count (plt/uL)^a	N/A	1.00	0.996-1.001	.15
Body mass index (kg/m²)^a	N/A	1.01	0.95-1.06	.85
Histology
Nonurothelial	11/80 (13.8)	3.17	1.52-6.60	.002
Urothelial	38/863 (4.4)	1.0	ref	ref
CVD or CVD risk factors
Yes	34/496 (6.9)	2.06	1.07-3.97	.03
No	15/447 (3.4)	1.0	ref	ref
Renal dysfunction
Yes	8/77 (10.4)	1.98	0.86-4.56	.11
No	41/866 (4.7)	1.0	ref	ref

Abbreviations: CI, confidence interval; CVD, cardiovascular disease; OR, odds ratio; VTE, venous thromboembolism; WBC, white blood cell.

^aCalculated as continuous variables.

Discussion

The Khorana score was developed to improve stratification of VTE risk in ambulatory patients with cancer planning on receiving chemotherapy.⁴ One potential application of the Khorana score is to identify a subset of patients with cancer at particularly high risk of VTE for enrollment in prospective primary thromboprophylaxis studies. Two randomized clinical trials of primary thromboprophylaxis in multiple solid tumors have demonstrated a statistically significant decrease in VTE rates.^9,10 However, the absolute benefit from thromboprophylaxis was only approximately 2% in both studies, with the placebo group in both studies having a VTE rate of less than 4% at a median follow-up of 3.5 months. Consequently, primary thromboprophylaxis has not been adopted into routine clinical practice nor recommended by consensus guidelines for VTE prevention.^11,12 In their original analysis, Khorana et al demonstrated that patients with a high-risk score had a VTE rate of 7.1% and 6.7%, whereas the intermediate-risk score patients had a VTE rate of 1.8% and 2.0% in the development and validation cohorts, respectively.⁴ Subsequently, the CATS study showed a VTE incidence rate of 17.7% at 6 months in patients with a high-risk Khorana score.⁵ These studies suggest that patients with high-risk Khorana scores may be ideal for clinical trial enrollment in primary thromboprophylaxis studies.

In our patient cohort, there was no statistically significant difference in overall VTE rates between Khorana high- and intermediate-risk patients. However, when we evaluated the Khorana score’s ability to predict early VTE risk, the Khorana score was able to stratify VTE risk in patients with metastatic UC/VH. In the first 3 months, patients with metastatic UC/VH with a high-risk Khorana score had a VTE rate of 8.0%, comparable to the VTE rate in the original Khorana analysis and higher than the rates seen in unselected randomized clinical trials. Therefore, the Khorana score could be used to identify patients with metastatic UC/VH who could be candidates for primary thromboprophylaxis clinical trials.

The Khorana score’s ability to predict for early VTE may come as a result of the variables in the model also being prognostic for worse outcomes. For example, a hemoglobin level <10 g/dL has been validated as a poor prognostic factor in patients with metastatic UC who have progressed on platinum-based chemotherapy.¹³ Of all the Khorana variables, leukocytosis has the strongest evidence for association with early mortality. Connolly et al reported that patients with leukocytosis initiating chemotherapy had a 2.2-fold increased risk of early mortality, with a median time to death of 38 days.¹⁴ Furthermore, a case series of 9 patients with UC with unexplained leukocytosis and neutrophilia demonstrated a median overall survival of 71 days from the development of leukocytosis to death.¹⁵ Thus, early VTE may be associated with aggressive disease, and patients with late VTE may have a better prognosis malignancy, with VTE likely driven by other factors.

In our multivariate analysis, the only Khorana risk score variable found to be significantly associated with increased risk for early VTE was WBC count. The mechanism underlying the association of leukocytosis, neutrophilia, and VTE is unclear. One possible explanation is through tumor-derived granulocyte colony-stimulating factor (G-CSF) leading to production of neutrophilic extracellular traps (NETs).¹⁶ NETs are released from highly activated neutrophils and shown to be harmful to the vasculature through promotion of thrombus formation by providing the nidus for platelet adhesion, activation, and aggregation.^17,18 Furthermore, in a G-CSF producing mouse model of mammary carcinoma, administration of G-CSF neutralizing antibody reduced the peripheral blood neutrophil count and the ability of neutrophils to undergo NET generation, suggesting that activation of neutrophils with G-CSF is important for NET formation.¹⁹ Lastly, NET formation coincided with development of venous thrombi in the lung. Taken together, these studies suggest that NETs may play a role in VTE development in patients with cancer with leukocytosis and neutrophilia.

There were several limitations to our study. First, the study is limited by its retrospective nature and the inherent confounders associated with such analyses. In addition, clinical characteristics that may predispose patients to VTE, such as poor Eastern Cooperative Oncology Group (ECOG) performance status or inherited thrombophilia, had significant missing data and were not included in the analysis. Although VTE for this analysis used a uniform definition, each event was ascribed by an independent investigator, and central radiographic adjudication was not performed. Finally, the ability to find statistical significance in some of our variables in the early and late subgroup analyses may have been limited by absolute incidence rates for patients with specific variables, in particular renal dysfunction.

In summary, the Khorana score does not adequately stratify cumulative VTE risk in patients with metastatic UC/VH overall. However, it appears to be able to predict early VTE, thus, it is reasonable to use the Khorana score to identify a high-risk population for a primary thromboprophylaxis clinical trial of patients initiating the first-line chemotherapy. However, it is possible that the reason the Khorana score is able to predict for early VTE is because the variables within the model also likely predict for early mortality, and VTE may be associated with poor prognosis disease. Finally, in patients with metastatic UC/VH, further investigation into the association between leukocytosis and VTE should be undertaken to better understand and treat the underlying biological mechanism.

Footnotes

Authors’ Note

The authors listed below have made substantial contributions to the intellectual content of the article in the various sections described as follows: Conception and design: J.D. Ramos, M.D. Galsky, and E.Y. Yu. Analysis or interpretation of data: J.D. Ramos, M.F. Casey, M.D. Galsky, and E.Y. Yu. Critical writing or revising the intellectual content: J.D. Ramos, M.F. Casey, A. Bamias, U. De Giorgi, J. Bellmunt, L.C. Harshman, S. Ladoire, Y. Wong, A.S. Alva, J.E. Rosenberg, M.D. Galsky, and E.Y. Yu. Final approval of the version to be published: J.D. Ramos, M.F. Casey, A. Bamias, U. De Giorgi, J. Bellmunt, L.C. Harshman, S. Ladoire, Y. Wong, A.S. Alva, J.E. Rosenberg, M.D. Galsky, and E.Y. Yu.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JDR is funded by T32 CA009515 NIH Training Grant.

References

Prandoni

Lensing

Piccioli

. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–3488.

Sorensen

Mellemkjaer

Olsen

Baron

. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–1850.

Timp

Braekkan

Versteeg

Cannegieter

. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712–1723.

Khorana

Kuderer

Culakova

Lyman

Francis

. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907.

Dunkler

Marosi

. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–5382.

Galsky

Pal

Chowdhury

; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015;121(15):2586–2593.

Ramos

Casey

Crabb

; RISC Investigators. Impact of chemotherapy on venous thromboembolism and prognostic implications in patients with metastatic urinary tract tumors. In: American Society of Clinical Oncology Genitourinary Cancers Symposium, 26–28 2 2015, Orlando, FL.

Charlson

Pompei

Ales

MacKenzie

. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.

Agnelli

George

Kakkar

; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601–609.

10.

Agnelli

Gussoni

Bianchini

; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943–949.

11.

Lyman

Khorana

Kuderer

; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189–2204.

12.

Streiff

Holmstrom

Ashrani

. Cancer-associated venous thromboembolic disease, version 1.2015. J Natl Compr Canc Netw. 2015;13(9):1079–1095.

13.

Bellmunt

Choueiri

Fougeray

. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850–1855.

14.

Connolly

Khorana

Kuderer

Culakova

Francis

Lyman

. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res. 2010;126(2):113–118.

15.

Izard

Gore

Mostaghel

. Persistent, unexplained leukocytosis is a paraneoplastic syndrome associated with a poor prognosis in patients with urothelial carcinoma. Clin Genitourin Cancer. 2015;13(4):e253–e258.

16.

Hisada

Geddings

Mackman

. Venous thrombosis and cancer: from mouse models to clinical trials. J Thromb Haemost. 2015;13(8):1372–1382.

17.

Fuchs

Brill

Duerschmied

. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107(36):15880–15885.

18.

Martinod

Wagner

. Thrombosis: tangled up in NETs. Blood. 2014;123(18):2768–2776.

19.

Demers

Krause

Schatzberg

. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012;109(32):13076–13081.